| Literature DB >> 31077593 |
Kelly Kisling1, Lifei Zhang1, Simona F Shaitelman2, David Anderson3, Tselane Thebe3, Jinzhong Yang1, Peter A Balter1, Rebecca M Howell1, Anuja Jhingran2, Kathleen Schmeler4, Hannah Simonds5, Monique du Toit6, Christoph Trauernicht6, Hester Burger7, Kobus Botha7, Nanette Joubert7, Beth M Beadle8, Laurence Court1.
Abstract
PURPOSE: Breast cancer is the most common cancer in women globally and radiation therapy is a cornerstone of its treatment. However, there is an enormous shortage of radiotherapy staff, especially in low- and middle-income countries. This shortage could be ameliorated through increased automation in the radiation treatment planning process, which may reduce the workload on radiotherapy staff and improve efficiency in preparing radiotherapy treatments for patients. To this end, we sought to create an automated treatment planning tool for postmastectomy radiotherapy (PMRT).Entities:
Keywords: automated treatment planning; postmastectomy radiotherapy
Mesh:
Year: 2019 PMID: 31077593 PMCID: PMC6739169 DOI: 10.1002/mp.13586
Source DB: PubMed Journal: Med Phys ISSN: 0094-2405 Impact factor: 4.071
Figure 1Overview of the method for automated planning of postmastectomy radiotherapy. OARs, organs at risk; BEV, beam's eye view; ROIs, regions of interest. [Color figure can be viewed at wileyonlinelibrary.com]
Figure 2Beam's eye view of supraclavicular fields for the original match line plan (left) and alternative match line plan (right) for the same patient. The contour of the level III axillary nodes are shown projected in orange. [Color figure can be viewed at wileyonlinelibrary.com]
Hypofractionated PMRT dose objectives for target coverage and organs‐at‐risk.
| Structure | Dose metric | Preferred objective | Acceptable limit |
|---|---|---|---|
| Targets | Volume > 95% Rx | >95% | n/a |
| Targets | Volume > 90% Rx | n/a | >90% |
| Heart | Mean dose | <4 Gy | <6 Gy |
| Volume > 25 Gy | <7% | <10% | |
| Ipsilateral lung | Volume > 17 Gy | <35% | <40% |
PMRT, postmastectomy radiotherapy; Rx, prescription; n/a, not applicable.
Thresholds for automated verification tests of automated PMRT plan quality.
| Test object | Test metric | Threshold |
|---|---|---|
| Maximum dose (composite) | Point dose | >116% of prescription |
| Maximum dose (tangential plan) | Point dose | >112% of prescription |
| Maximum dose (SCV plan) | Point dose | >112% of prescription |
| Heart dose | Mean dose | <4 Gy |
| Volume > 25 Gy | <7% | |
| Ipsilateral lung dose | Volume > 17 Gy | <30% |
| Lung in SCV field | Projection height | <4 cm |
| SCV gantry angle | Angle off vertical | >15° |
PMRT, postmastectomy radiotherapy; SCV, supraclavicular.
Figure 3Comparison of the automatically generated and physician‐approved contours of the heart and ipsilateral lung. The top row shows the following results of the geometric comparisons: Dice similarity coefficient (DSC; left), mean surface distance (MSD; center), and Hausdorff distance (HD; right). The bottom row shows the following results of the dosimetric comparisons: mean OAR dose (left) and dose–volume histogram metric (right). The absolute difference in metrics was the results for the physician‐approved contour minus that for the automatically generated contour for the same plan. [Color figure can be viewed at wileyonlinelibrary.com]
Figure 4The final dose metrics for the ten automatically planned treatments. The dose–volume histogram (DVH) metrics (top left), mean dose delivered to the heart and ipsilateral lung (top right), coverage of targets by 95% or the prescription dose (bottom left), and maximum doses for the tangential and SCV plans and for a composite of the two plans (bottom right) are shown. OARs, organs at risk; SCV, supraclavicular; Ax3, level III axillary; Rx, prescription. [Color figure can be viewed at wileyonlinelibrary.com]